Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rocket Pharmaceuticals, Inc.

2.90
+0.02000.69%
Post-market: 2.87-0.0266-0.92%16:55 EDT
Volume:1.75M
Turnover:5.09M
Market Cap:312.44M
PE:-1.11
High:2.96
Open:2.91
Low:2.85
Close:2.88
Loading ...

Rocket Pharmaceuticals CFO John Militello Reports Disposal of Common Shares

Reuters
·
23 May

Rocket Pharmaceuticals' General Counsel Martin Wilson Reports Disposal of Common Shares

Reuters
·
21 May

Jonathan David Schwartz, Chief Medical & Gene Therapy Officer, Reports Disposal of Common Shares of Rocket Pharmaceuticals Inc

Reuters
·
21 May

CEO Gaurav Shah Reports Disposal of Common Shares of Rocket Pharmaceuticals Inc

Reuters
·
21 May

Regenxbio Signs Royalty Deal Worth Up to $250 Million With Healthcare Royalty

MT Newswires Live
·
20 May

Chardan Ups Price Target on Rocket Pharmaceuticals to $46 From $45, Maintains Buy Rating

MT Newswires Live
·
16 May

Rocket Pharmaceuticals price target raised to $46 from $45 at Chardan

TIPRANKS
·
16 May

Scotiabank Keeps Their Buy Rating on Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
16 May

Rocket Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
16 May

Stock Track | Rocket Pharmaceuticals Soars 5.20% on Promising Phase 1 Clinical Trial Results for RP-A601

Stock Track
·
16 May

BRIEF-Rocket Pharmaceuticals Presents Preliminary Data From Phase 1 Clinical Trial of RP-A601 For PKP2 Arrhythmogenic Cardiomyopathy At 28th Annual Meeting Of The American Society Of Gene And Cell Therapy

Reuters
·
16 May

Rocket Pharmaceuticals reports preliminary data from Phase 1 RP-A601 trial

TIPRANKS
·
16 May

Rocket Pharmaceuticals Presents Preliminary Data From Phase 1 Clinical Trial of Rp-a601 for Pkp2 Arrhythmogenic Cardiomyopathy at 28TH Annual Meeting of the American Society of Gene and Cell Therapy

THOMSON REUTERS
·
16 May

Rocket Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank

Dow Jones
·
12 May

Rocket Pharmaceuticals Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
12 May

Chardan Adjusts Price Target on Rocket Pharmaceuticals to $45 From $54, Maintains Buy Rating

MT Newswires Live
·
12 May

Rocket Pharmaceuticals Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
10 May

Rocket Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

Rocket Pharmaceuticals Reports Q1 2025 Financial Results; Cash Position at $318.2 Million, Operational Runway Extended to Q4 2026

Reuters
·
09 May

Rocket Pharmaceuticals Q1 EPS $(0.56) Beats $(0.63) Estimate

Benzinga
·
09 May